What question did this study set out to answer?

To develop a system that activates interferon alpha (IFNα) and PD-1 blockade specifically within tumors while minimizing systemic side effects.

April 5, 2026Cancer Research0 citations

Interferon-α and PD-1 Blockade Mutually Mask Each Other in Tumor Activation

Abstract 4344: Interferon-α and PD-1 blockade mutually mask each other in a tumor-activated manner

View Full Paper

Ask AI

Bookmark

Authors

This work demonstrates a dual-masking strategy that enhances tumor immunity in cancer, suggesting a safer immunotherapy approach.

To develop a system that activates interferon alpha (IFNα) and PD-1 blockade specifically within tumors while minimizing systemic side effects.
Developed a tumor-activated IFNα-PD-1 fusion with dual masking.
Integrated IFNα into anti-PD-1 antibodies to prevent premature activation.
Utilized proteolytic cleavage to reactivate IFNα and PD-1 in the tumor microenvironment.
Conducted ELISA assays to assess antigen-binding activity and MHC I expression.
Inactivated lockers showed over 20-fold reduction in binding activity compared to parental antibodies.
Protease activation restored binding to levels similar to parental forms.
The activated fusion induced significant upregulation of MHC I in melanoma cells.
In vivo, the fusion led to superior tumor suppression and increased T cell infiltration with low systemic toxicity.

Chao et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

April 5, 2026Cancer Research0 citations

Abstract 4344: Interferon-α and PD-1 blockade mutually mask each other in a tumor-activated manner

View Full Paper

Ask AI

Bookmark

Authors

This work demonstrates a dual-masking strategy that enhances tumor immunity in cancer, suggesting a safer immunotherapy approach.

To develop a system that activates interferon alpha (IFNα) and PD-1 blockade specifically within tumors while minimizing systemic side effects.
Developed a tumor-activated IFNα-PD-1 fusion with dual masking.
Integrated IFNα into anti-PD-1 antibodies to prevent premature activation.
Utilized proteolytic cleavage to reactivate IFNα and PD-1 in the tumor microenvironment.
Conducted ELISA assays to assess antigen-binding activity and MHC I expression.
Inactivated lockers showed over 20-fold reduction in binding activity compared to parental antibodies.
Protease activation restored binding to levels similar to parental forms.
The activated fusion induced significant upregulation of MHC I in melanoma cells.
In vivo, the fusion led to superior tumor suppression and increased T cell infiltration with low systemic toxicity.

Chao et al. (2026) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark